{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:53:54Z","timestamp":1740142434813,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"China National Key R&D Program during the 14th Five-year Plan Period","award":["2022YFC2504804"],"award-info":[{"award-number":["2022YFC2504804"]}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2021-2IM-I-039"],"award-info":[{"award-number":["2021-2IM-I-039"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Braz J Microbiol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s42770-023-01167-z","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T06:01:25Z","timestamp":1699336885000},"page":"2597-2602","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In vitro combination with doxycycline plus antifungals against clinical Mucorales pathogens"],"prefix":"10.1007","volume":"54","author":[{"given":"Meijie","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balaji","family":"Pathakumari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weida","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5330-8864","authenticated-orcid":false,"given":"Guanzhao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,7]]},"reference":[{"key":"1167_CR1","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/s1473-3099(19)30312-3","volume":"19","author":"OA Cornely","year":"2019","unstructured":"Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, Hoenigl M, Jensen HE, Lagrou K, Lewis RE et al (2019) Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 19:e405\u2013e421. https:\/\/doi.org\/10.1016\/s1473-3099(19)30312-3","journal-title":"Lancet Infect Dis"},{"key":"1167_CR2","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1111\/myc.13338","volume":"64","author":"R Pal","year":"2021","unstructured":"Pal R, Singh B, Bhadada SK, Banerjee M, Bhogal RS, Hage N, Kumar A (2021) COVID-19-associated mucormycosis: an updated systematic review of literature. Mycoses 64:1452\u20131459. https:\/\/doi.org\/10.1111\/myc.13338","journal-title":"Mycoses"},{"key":"1167_CR3","unstructured":"WHO releases first-ever list of health-threatening fungi. Available online https:\/\/www.who.int\/news\/item\/25-10-2022-who-releases-first-ever-list-of-health-threatening-fungi2022. Accessed 25 Oct 2022"},{"key":"1167_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cmi.2018.07.011","volume":"25","author":"W Jeong","year":"2019","unstructured":"Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DCM, Chen SC (2019) The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect 25:26\u201334. https:\/\/doi.org\/10.1016\/j.cmi.2018.07.011","journal-title":"Clin Microbiol Infect"},{"key":"1167_CR5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11046-018-0273-6","volume":"184","author":"MH Fu","year":"2019","unstructured":"Fu MH, Liu J, Liang GZ, Li CR, Zhu XM, Wang L, Chen H, Hu WL, Lv GX, Liu WD (2019) Successful treatment of eczema-like mucormycosis in a child by combination of intravenous drip and percutaneous injection amphotericin B. Mycopathologia 184:309\u2013313. https:\/\/doi.org\/10.1007\/s11046-018-0273-6","journal-title":"Mycopathologia"},{"key":"1167_CR6","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11046-017-0219-4","volume":"183","author":"GZ Liang","year":"2018","unstructured":"Liang GZ, Xu WQ, Zheng XL, Mei H, Lv GX, Shen YN, Li DM, Liu WD (2018) Successful treatment by surgery of a primary cutaneous mucormycosis caused by mucor irregularis. Mycopathologia 183:445\u2013449. https:\/\/doi.org\/10.1007\/s11046-017-0219-4","journal-title":"Mycopathologia"},{"key":"1167_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010858","volume":"18","author":"C Smith","year":"2022","unstructured":"Smith C, Lee SC (2022) Current treatments against mucormycosis and future directions. PLoS Pathog 18:e1010858. https:\/\/doi.org\/10.1371\/journal.ppat.1010858","journal-title":"PLoS Pathog"},{"key":"1167_CR8","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1128\/aac.00452-07","volume":"51","author":"NG Almyroudis","year":"2007","unstructured":"Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S (2007) In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 51:2587\u20132590. https:\/\/doi.org\/10.1128\/aac.00452-07","journal-title":"Antimicrob Agents Chemother"},{"key":"1167_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1128\/jcm.06133-11","volume":"50","author":"RG Vitale","year":"2012","unstructured":"Vitale RG, de Hoog GS, Schwarz P, Dannaoui E, Deng S, Machouart M, Voigt K, van de Sande WW, Dolatabadi S, Meis JF et al (2012) Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales. J Clin Microbiol 50:66\u201375. https:\/\/doi.org\/10.1128\/jcm.06133-11","journal-title":"J Clin Microbiol"},{"key":"1167_CR10","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1128\/aac.01539-06","volume":"51","author":"M Torres-Narbona","year":"2007","unstructured":"Torres-Narbona M, Guinea J, Mart\u00ednez-Alarc\u00f3n J, Pel\u00e1ez T, Bouza E (2007) In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. Antimicrob Agents Chemother 51:1126\u20131129. https:\/\/doi.org\/10.1128\/aac.01539-06","journal-title":"Antimicrob Agents Chemother"},{"key":"1167_CR11","doi-asserted-by":"publisher","first-page":"7882","DOI":"10.1128\/aac.02107-15","volume":"59","author":"A Chowdhary","year":"2015","unstructured":"Chowdhary A, Singh PK, Kathuria S, Hagen F, Meis JF (2015) Comparison of the EUCAST and CLSI broth microdilution methods for testing isavuconazole, posaconazole, and amphotericin b against molecularly identified mucorales species. Antimicrob Agents Chemother 59:7882\u20137887. https:\/\/doi.org\/10.1128\/aac.02107-15","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 5","key":"1167_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1469-0691.2009.02984.x","volume":"15","author":"A Alastruey-Izquierdo","year":"2009","unstructured":"Alastruey-Izquierdo A, Castelli MV, Cuesta I, Zaragoza O, Monz\u00f3n A, Mellado E, Rodr\u00edguez-Tudela JL (2009) In vitro activity of antifungals against Zygomycetes. Clin Microbiol Infect 15(Suppl 5):71\u201376. https:\/\/doi.org\/10.1111\/j.1469-0691.2009.02984.x","journal-title":"Clin Microbiol Infect"},{"key":"1167_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/jac\/dkg020","volume":"51","author":"E Dannaoui","year":"2003","unstructured":"Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE (2003) In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 51:45\u201352. https:\/\/doi.org\/10.1093\/jac\/dkg020","journal-title":"J Antimicrob Chemother"},{"key":"1167_CR14","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1439-0507.2005.01132.x","volume":"48","author":"J Singh","year":"2005","unstructured":"Singh J, Rimek D, Kappe R (2005) In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method. Mycoses 48:246\u2013250. https:\/\/doi.org\/10.1111\/j.1439-0507.2005.01132.x","journal-title":"Mycoses"},{"key":"1167_CR15","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/myc.13335","volume":"64","author":"SM Rudramurthy","year":"2021","unstructured":"Rudramurthy SM, Hoenigl M, Meis JF, Cornely OA, Muthu V, Gangneux JP, Perfect J, Chakrabarti A (2021) ECMM\/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Mycoses 64:1028\u20131037. https:\/\/doi.org\/10.1111\/myc.13335","journal-title":"Mycoses"},{"key":"1167_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.31486\/toj.21.0099","volume":"22","author":"DAS Hammoudi","year":"2022","unstructured":"Hammoudi DAS, Morar MM, Garbuzov A, Urias D, Katira KM (2022) Lower extremity salvage in a diabetic patient with cutaneous mucormycosis and COVID-19 after open patella fracture. Ochsner J 22:163\u2013168. https:\/\/doi.org\/10.31486\/toj.21.0099","journal-title":"Ochsner J"},{"key":"1167_CR17","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1111\/jdv.14345","volume":"31","author":"M Henehan","year":"2017","unstructured":"Henehan M, Montuno M, De Benedetto A (2017) Doxycycline as an anti-inflammatory agent: updates in dermatology. J Eur Acad Dermatol Venereol 31:1800\u20131808. https:\/\/doi.org\/10.1111\/jdv.14345","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1167_CR18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/mmy\/myy008","volume":"57","author":"RW Hooper","year":"2019","unstructured":"Hooper RW, Ashcraft DS, Pankey GA (2019) In vitro synergy with fluconazole plus doxycycline or tigecycline against clinical Candida glabrata isolates. Med Mycol 57:122\u2013126. https:\/\/doi.org\/10.1093\/mmy\/myy008","journal-title":"Med Mycol"},{"key":"1167_CR19","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ijantimicag.2017.10.017","volume":"51","author":"TP Venturini","year":"2018","unstructured":"Venturini TP, Al-Hatmi AMS, Rossato L, Azevedo MI, Keller JT, Weiblen C, Santurio JM, Alves SH (2018) Do antibacterial and antifungal combinations have better activity against clinically relevant fusarium species? In vitro synergism. Int J Antimicrob Agents 51:784\u2013788. https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.10.017","journal-title":"Int J Antimicrob Agents"},{"key":"1167_CR20","unstructured":"CL.S.I. (2018) M38Ed3; Reference Method for Broth Dilution Antifungal Susceptibilty Testing of Filamentous Fungi. Clinical and Laboratory Standards Institute: Malvern, PA, USA"},{"key":"1167_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkg301","volume":"52","author":"FC Odds","year":"2003","unstructured":"Odds FC (2003) Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52:1. https:\/\/doi.org\/10.1093\/jac\/dkg301","journal-title":"J Antimicrob Chemother"},{"key":"1167_CR22","unstructured":"CL.S.I. (2020) M61Ed2; Performance Standards for Antifungal Susceptibility Testing of Filamentous Fungi. Clinical and Laboratory Standards Institute: Malvern, PA, USA"},{"key":"1167_CR23","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1128\/aac.06017-11","volume":"56","author":"A Fiori","year":"2012","unstructured":"Fiori A, Van Dijck P (2012) Potent synergistic effect of doxycycline with fluconazole against Candida albicans is mediated by interference with iron homeostasis. Antimicrob Agents Chemother 56:3785\u20133796. https:\/\/doi.org\/10.1128\/aac.06017-11","journal-title":"Antimicrob Agents Chemother"},{"key":"1167_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01230-21","volume":"59","author":"H Badali","year":"2021","unstructured":"Badali H, Ca\u00f1ete-Gibas C, McCarthy D, Patterson H, Sanders C, David MP, Mele J, Fan H, Wiederhold NP (2021) Epidemiology and antifungal susceptibilities of mucoralean fungi in clinical samples from the United States. J Clin Microbiol 59:e0123021. https:\/\/doi.org\/10.1128\/jcm.01230-21","journal-title":"J Clin Microbiol"},{"key":"1167_CR25","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1128\/jcm.02326-10","volume":"49","author":"BM Hemashettar","year":"2011","unstructured":"Hemashettar BM, Patil RN, O\u2019Donnell K, Chaturvedi V, Ren P, Padhye AA (2011) Chronic rhinofacial mucormycosis caused by Mucor irregularis (Rhizomucor variabilis) in India. J Clin Microbiol 49:2372\u20132375. https:\/\/doi.org\/10.1128\/jcm.02326-10","journal-title":"J Clin Microbiol"},{"key":"1167_CR26","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1128\/aac.01467-08","volume":"53","author":"A Alastruey-Izquierdo","year":"2009","unstructured":"Alastruey-Izquierdo A, Castelli MV, Cuesta I, Monzon A, Cuenca-Estrella M, Rodriguez-Tudela JL (2009) Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. Antimicrob Agents Chemother 53:1686\u20131689. https:\/\/doi.org\/10.1128\/aac.01467-08","journal-title":"Antimicrob Agents Chemother"},{"key":"1167_CR27","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11046-021-00551-3","volume":"186","author":"X Tang","year":"2021","unstructured":"Tang X, Guo P, Wong H, Xie J, Han J, Xu Y, Zhou H (2021) Vacuum-assisted closure and skin grafting combined with amphotericin B for successful treatment of an immunocompromised patient with cutaneous mucormycosis caused by Mucor irregularis: a case report and literature review. Mycopathologia 186:449\u2013459. https:\/\/doi.org\/10.1007\/s11046-021-00551-3","journal-title":"Mycopathologia"},{"key":"1167_CR28","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1128\/aac.44.9.2435-2441.2000","volume":"44","author":"F Barchiesi","year":"2000","unstructured":"Barchiesi F, Schimizzi AM, Caselli F, Novelli A, Fallani S, Giannini D, Arzeni D, Di Cesare S, Di Francesco LF, Fortuna M et al (2000) Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob Agents Chemother 44:2435\u20132441. https:\/\/doi.org\/10.1128\/aac.44.9.2435-2441.2000","journal-title":"Antimicrob Agents Chemother"},{"key":"1167_CR29","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1128\/aac.48.9.3312-3316.2004","volume":"48","author":"F Barchiesi","year":"2004","unstructured":"Barchiesi F, Spreghini E, Schimizzi AM, Maracci M, Giannini D, Carle F, Scalise G (2004) Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection. Antimicrob Agents Chemother 48:3312\u20133316. https:\/\/doi.org\/10.1128\/aac.48.9.3312-3316.2004","journal-title":"Antimicrob Agents Chemother"},{"key":"1167_CR30","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/phar.2625","volume":"41","author":"MR Bidell","year":"2021","unstructured":"Bidell MR, Lodise TP (2021) Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: focus on doxycycline, minocycline, and omadacycline. Pharmacotherapy 41:915\u2013931. https:\/\/doi.org\/10.1002\/phar.2625","journal-title":"Pharmacotherapy"},{"key":"1167_CR31","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1001\/jama.2021.17633","volume":"326","author":"DZ Eichenfield","year":"2021","unstructured":"Eichenfield DZ, Sprague J, Eichenfield LF (2021) Management of acne vulgaris: a review. JAMA 326:2055\u20132067. https:\/\/doi.org\/10.1001\/jama.2021.17633","journal-title":"JAMA"},{"key":"1167_CR32","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ijantimicag.2009.04.011","volume":"34","author":"MH Miceli","year":"2009","unstructured":"Miceli MH, Bernardo SM, Lee SA (2009) In vitro analyses of the combination of high-dose doxycycline and antifungal agents against Candida albicans biofilms. Int J Antimicrob Agents 34:326\u2013332. https:\/\/doi.org\/10.1016\/j.ijantimicag.2009.04.011","journal-title":"Int J Antimicrob Agents"},{"key":"1167_CR33","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1136\/bjo.2008.142364","volume":"93","author":"S Day","year":"2009","unstructured":"Day S, Lalitha P, Haug S, Fothergill AW, Cevallos V, Vijayakumar R, Prajna NV, Acharya NR, McLeod SD, Lietman TM (2009) Activity of antibiotics against Fusarium and Aspergillus. Br J Ophthalmol 93:116\u2013119. https:\/\/doi.org\/10.1136\/bjo.2008.142364","journal-title":"Br J Ophthalmol"},{"key":"1167_CR34","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/jac\/dkn473","volume":"63","author":"T Stergiopoulou","year":"2009","unstructured":"Stergiopoulou T, Meletiadis J, Sein T, Papaioannidou P, Tsiouris I, Roilides E, Walsh TJ (2009) Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus. J Antimicrob Chemother 63:343\u2013348. https:\/\/doi.org\/10.1093\/jac\/dkn473","journal-title":"J Antimicrob Chemother"},{"key":"1167_CR35","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1099\/mic.0.2007\/013805-0","volume":"154","author":"BG Oliver","year":"2008","unstructured":"Oliver BG, Silver PM, Marie C, Hoot SJ, Leyde SE, White TC (2008) Tetracycline alters drug susceptibility in Candida albicans and other pathogenic fungi. Microbiology (Reading) 154:960\u2013970. https:\/\/doi.org\/10.1099\/mic.0.2007\/013805-0","journal-title":"Microbiology (Reading)"}],"container-title":["Brazilian Journal of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42770-023-01167-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42770-023-01167-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42770-023-01167-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T03:21:38Z","timestamp":1701400898000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42770-023-01167-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,7]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1167"],"URL":"https:\/\/doi.org\/10.1007\/s42770-023-01167-z","relation":{},"ISSN":["1517-8382","1678-4405"],"issn-type":[{"type":"print","value":"1517-8382"},{"type":"electronic","value":"1678-4405"}],"subject":[],"published":{"date-parts":[[2023,11,7]]},"assertion":[{"value":"27 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}